Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.
16 April 2018
Highlights: • Sales of Ellex iTrackTM up 57% in the USA and 40% globally compared with the pcp • Improved new customer acquisition and revenues for Ellex iTrackTM in all but one US territory demonstrates improved geographic penetration • Global sales of Ellex glaucoma business reached a record US$22.3 million with an acceleration to 40% growth compared with the pcp Adelaide, Australia 16 April 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced a sales update for Ellex iTrackTM, and its wider glaucoma business, for the 9 months ended 31 March 2018. The wider Ellex glaucoma business comprises the Ellex iTrackTM minimally invasive glaucoma surgery device (MIGS) and the Ellex tangoTM SLT laser for early stage disease. Ellex holds a unique global position for early to mid-stage restorative glaucoma therapy. Ellex iTrackTM Sales Update Ellex iTrackTM global sales were US$6.1 million for the
Ellex’s Patented Glaucoma Treatment Technologies to be Spotlighted at Major US Tradeshow, ASCRS 2018
10 April 2018
Adelaide, Australia 10 April 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that it will showcase its proprietary glaucoma treatment portfolio, including its breakthrough iTrack™ minimally invasive glaucoma surgery (MIGS) technology, at the 2018 annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Washington, 13-17 April 2018. Also on display will be Ellex’s proprietary Reflex Technology™ for the treatment of symptomatic floater patients. With more than 9000 members, the ASCRS is considered to be the preeminent educational society for anterior segment (front of the eye) surgeons in the USA. The 2018 meeting of ASCRS provides a strong platform for Ellex to target cataract and refractive surgeons with the Company’s iTrack™ and Ellex tangoTM Selective Light Therapy portfolios for glaucoma, as well as its Reflex Technology™ portfolio for floater management. E
23 March 2018
Adelaide, Australia 23 March 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the agenda for a panel discussion on the Company’s proprietary 2RT® Retinal Rejuvenation Therapy at the European Laser Innovation Forum to be held in Nice, France on 24 March 2018. 2RT® is Ellex’s breakthrough laser therapy which has the potential to positively influence the lives of millions of people suffering from age-related macular degeneration (AMD) in its early stages. An interventional treatment, 2RT® may allow physicians to treat patients at a stage of the disease for which there is no alternative therapy. It may also defer or eliminate the need for expensive, invasive pharmaceuticals that are currently used in the late stage of the disease. Sponsored by Ellex, the forum will enlist a panel of world-renowned faculty, including John Marshall, PhD, FRCPath, to share their collective experiences and latest u
Annual Report 2017
View Share Price
Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.